Nautilus Biotechnology (NAUT) Net Income (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Net Income of -$50.5 million for Q2 2026, up 4.44% sequentially from -$52.9 million in Q2 2025, and up 4.44% YoY from -$48.4 million in Q2 2025.
Nautilus Biotechnology (NAUT) Net Income (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Net Income for 4 years, with the latest figure at -$50.5 million in Q2 2026.
- Quarterly Net Income rose 4.44% year-over-year to -$50.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$50.5 million (up 4.44% YoY) and the FY2020 annual result came in at -$41.3 million, changed N/A from the prior year.
- Net Income advanced to -$50.5 million in Q2 2026 per NAUT's latest filing, from -$52.9 million in the prior quarter.
- Over five years, Net Income peaked at -$50.5 million in Q2 2026 and troughed at -$52.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | -14.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.55 Mn |
| Jun 30, 2025 | -52.90 Mn |
| Mar 31, 2021 | -2.08 Mn |
| Dec 31, 2020 | -1.38 Mn |
| Sep 30, 2020 | -586,388.00 |